News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,237 Results
Type
Article (13587)
Company Profile (110)
Press Release (247540)
Section
Business (87949)
Career Advice (461)
Deals (15324)
Drug Delivery (64)
Drug Development (36535)
Employer Resources (49)
FDA (6259)
Job Trends (6184)
News (150035)
Policy (14010)
Tag
Academia (435)
Alliances (23093)
Alzheimer's disease (351)
Approvals (6253)
Artificial intelligence (61)
Bankruptcy (143)
Best Places to Work (4325)
Biotechnology (44)
Breast cancer (42)
Cancer (313)
Career advice (405)
Cell therapy (44)
Clinical research (30400)
Collaboration (153)
Compensation (62)
COVID-19 (747)
C-suite (52)
Data (342)
Diabetes (53)
Diagnostics (1236)
Drug pricing (57)
Earnings (31559)
Employer resources (43)
Events (36733)
Executive appointments (171)
FDA (6438)
Funding (104)
Gene therapy (59)
GLP-1 (292)
Government (1267)
Healthcare (3521)
Infectious disease (764)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5816)
Job creations (2049)
Job search strategy (372)
Layoffs (167)
Legal (3411)
Lung cancer (46)
Manufacturing (99)
Medical device (1261)
Medtech (1263)
Mergers & acquisitions (9541)
Metabolic disorders (166)
Neuroscience (449)
NextGen Class of 2024 (1580)
Non-profit (590)
Northern California (432)
Obesity (99)
Opinion (109)
Patents (52)
People (28455)
Pharmaceutical (64)
Phase I (7905)
Phase II (12856)
Phase III (11551)
Pipeline (183)
Policy (45)
Postmarket research (1399)
Preclinical (3164)
Radiopharmaceuticals (116)
Rare diseases (90)
Real estate (2630)
Regulatory (9823)
Research institute (562)
Resumes & cover letters (55)
Southern California (435)
Startups (1624)
United States (4253)
Vaccines (112)
Weight loss (78)
Date
Today (30)
Last 7 days (282)
Last 30 days (1242)
Last 365 days (12692)
2024 (11583)
2023 (14245)
2022 (19558)
2021 (20068)
2020 (19035)
2019 (14887)
2018 (11713)
2017 (13892)
2016 (13132)
2015 (15473)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (42)
Asia (19788)
Australia (2559)
California (1004)
Canada (598)
China (110)
Colorado (41)
Connecticut (41)
Europe (38776)
Florida (149)
Illinois (110)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (154)
Massachusetts (875)
Minnesota (56)
New Jersey (420)
New York (278)
North Carolina (277)
Northern California (432)
Pennsylvania (283)
South America (498)
Southern California (435)
Texas (137)
Virginia (40)
Washington State (70)
261,237 Results for "amneal pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Obesity Startup Metsera Inks Manufacturing Pact With Amneal on Heels of Phase I Readout
A week after it released positive early-stage data, Metsera has partnered with Amneal Pharmaceuticals in an effort to secure the development and supply of its investigational weight loss therapy MET-097.
October 1, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the addition of omalizumab, referencing XOLAIR ® , to its biosimilar pipeline.
July 1, 2024
·
7 min read
Parkinson’s disease
Amneal Wins FDA Approval for Extended-Release Oral Parkinson’s Drug
Crexont was previously rejected by the regulator in June 2023, citing insufficient safety data. However, Amneal Pharmaceuticals’ resubmission included findings from a healthy volunteer study.
August 8, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Amneal Releases 2023 Environmental, Social and Governance Report
Amneal Pharmaceuticals, Inc. announced the release of its fourth Environmental, Social and Governance Report.
June 28, 2024
·
9 min read
Press Releases
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.
July 1, 2024
·
7 min read
Business
Amneal Reports First Quarter 2024 Financial Results
Amneal Pharmaceuticals, Inc. announced its results for the first quarter ended March 31, 2024.
May 3, 2024
·
25 min read
Press Releases
Amneal Reports Third Quarter 2024 Financial Results
November 8, 2024
·
19 min read
Pharm Country
Amneal to Participate at Upcoming Investor Conference - May 22, 2024
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024.
May 22, 2024
·
1 min read
Policy
Teva Loses Inhaler Patent Case Against Amneal, Must Delete or Amend Orange Book Listing
Teva Pharmaceuticals lost its patent row with Amneal Pharmaceuticals on Monday as a New Jersey court ruled that some of Teva’s claims over its inhaler product ProAir HFA were improperly listed on the FDA’s Orange Book.
June 12, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
Amneal Pharmaceuticals, Inc. announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company’s total number of commercial injectable products available for the U.S. institutional market to over 40.
June 5, 2024
·
7 min read
1 of 26,124
Next
